Access to medication in Mexico: financing and equity
DOI:
https://doi.org/10.19136/hs.a15n2.1105Keywords:
access, inequality, inequity, financing, and pricesAbstract
Abstract: This paper presents some characteristics of the financing and access to medication in Mexico. It also shows the level of prices and costs of diabetes treatment. This study is based on the national survey about the income and expense of hoseholds from 1998 and 2010. The poorest households without social security, have an expense in medication relatively higher than the rest of the population which seems to be unfair. The cost of diabetes treatment with drugs without patent is too high.Downloads
Metrics
References
WHO and Health Action International (2008), Measuring medicine prices, availability, affordability and price components, 2nd edition, Geneva: WHO.
Lu, Y., Hernandez, P., Abegunde, D. & Edejer, T. (2011), The World Medicines situation 2011. Geneva: WHO
Sen, A. (1998), “Mortality as an indicator of economic success and failure” en The Economic Journal 108 (446):1-25.
Barba, C. (2012), “Regímenes de bienestar latinoamericanos: ¿universalismo o focalización?” en Calva, J [coordinador], Derechos sociales y desarrollo incluyente. Análisis estratégico para el desarrollo, México: Juan Pablos.
OCDE (2005), Estudios de la OCDE sobre los sistemas de salud: México, París: OCDE.
Narro J, Moctezuma D, Orozco L. (2010), “Hacia un nuevo modelo de seguridad social” en Economía UNAM, vol. 7. Pp. 7-33.
Molina R, Carbajal C, González E. (2008), “Competencia y precios en el mercado farmacéutico mexicano” en Salud Publica de México vol. 50. (sup 4) Pp.496-503
INEGI. Encuesta Nacional de Ingresos y Gastos de los Hogares de los años de 1998 y 2010.
MSH. Management Sciences for Health. International drug price indicator guide. 2010.
Catálogo de precios de Casa SABA. (Documento interno)
